|Day Low/High||57.52 / 58.16|
|52 Wk Low/High||56.66 / 69.75|
Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?
* The attractiveness of Coinbase Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...
Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.
Let's look at the companies that can go up, and the ones that can't.
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Prices have rallied from early March and are in a position to test their January highs.
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Traders should stay long and consider increasing their exposure.
A correction in EBS could soon set up an attractive opportunity.
This Friday several banks begin the unofficial kickoff of 'earnings season'.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.